BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

Novartis’ PD-1 misses in melanoma comboNovartis AG (NYSE:NVS; SIX:NOVN) said spartalizumab missed the primary endpoint of the Phase III COMBI-i trial in patients with untreated, unresectable BRAF V600-mutant cutaneous melanoma. The PD-1 inhibitor, in combination...
BioCentury | Sep 19, 2019
Distillery Therapeutics

DLK identified as target for Fragile X syndrome

...DISEASE CATEGORY: Neurology INDICATION: Fragile X syndrome Inhibiting DLK, a mediator of neuronal injury responses, could...
...X syndrome. In fruit flies with the disease, systemic DLK knockout or a tool compound DLK...
...DLK inhibitor GDC-0134 in Phase I testing for amyotrophic lateral sclerosis (ALS). TARGET/MARKER/PATHWAY: MAP kinase kinase kinase 12 (DLK; MAP3K12...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Neurology

...INDICATION: Pain Mouse studies suggest inhibiting DLK could help treat neuropathic pain associated with peripheral nerve...
...a DLK inhibitor, in Phase I testing for amyotrophic lateral sclerosis (ALS). TARGET/MARKER/PATHWAY: MAP kinase kinase kinase 12 (DLK; MAP3K12...
...alexander.chesler@nih.gov CONTACT: Claire E. Le Pichon, same affiliation as above email: claire.lepichon@nih.gov Jennie Walters National Institutes of Health MAP kinase kinase kinase 12 (DLK) (MAP3K12)...
BioCentury | Oct 10, 2017
Distillery Therapeutics

Neurology

...and motor strength compared with normal DLK expression. Also in the model, a previously reported DLK...
...DLK knockout decreased cognitive deficits. In a mouse model of acute optic nerve crush, the DLK...
...of GDC-0134 in ALS (see "Chronic Neuroprotection." BioCentury Innovations (Oct. 5, 2017)). TARGET/MARKER/PATHWAY: MAP kinase kinase kinase 12 (DLK; MAP3K12...
BioCentury | Oct 5, 2017
Translation in Brief

Chronic neuroprotection

...may play a broad role in driving neurodegeneration, regardless of the underlying cause. MAP kinase kinase kinase 12 (DLK; MAP3K12...
...model of AD, another DLK inhibitor decreased disease-associated activation of the JNK signaling pathway and DLK...
...2015) Winnie Pong, Staff Writer Califia Bio Inc. Genentech Inc. Roche University of California San Diego c-jun N-terminal kinase (JNK) MAP kinase kinase kinase 12 (MAP3K12) (DLK...
BioCentury | Jan 5, 2017
Translation in Brief

Two faces of tau

Contrary to the dogma that β-amyloid triggers Alzheimer’s disease (AD) by inducing phosphorylation of the neuronal protein tau, an Australian team has shown that the process can in fact be protective rather than pathogenic. In...
BioCentury | Nov 20, 2014
Distillery Therapeutics

Indication: Neurology

...information Neurology Neurology; Parkinson's disease (PD) MAP kinase kinase kinase 12 (MAP3K12; DLK) In vitro and mouse studies identified DLK...
...DLK) In vitro and mouse studies identified DLK inhibitors that could help treat neurodegenerative diseases. DLK...
...and subsequent medicinal chemistry on hits identified multiple di(pyridine-2-yl)amine analogs as selective nanomolar inhibitors of DLK...
BioCentury | Mar 7, 2013
Distillery Therapeutics

Indication: Ophthalmic disease

...status Publication and contact information Ophthalmic disease Glaucoma MAP kinase kinase kinase 12 (MAP3K12; DLK) Rodent studies suggest inhibiting DLK...
...effects that help treat glaucoma. In a mouse model for optic nerve damage, deletion of Dlk...
...of multiple kinases including DLK, prevented disease progression. Next steps could include developing more selective DLK...
BioCentury | Oct 8, 2012
Product Development

Contrarian thinking

...these targets in the Journal of Cell Biology. The study showed DLK ( MAP kinase kinase kinase 12 ; MAP3K12...
...Previous work by researchers at the Washington University School of Medicine suggested inhibition of DLK...
BioCentury | Feb 1, 2011
Company News

Map, Allergan to co-promote migraine candidate Levadex

Map Pharmaceuticals Inc. (NASDAQ:MAPP) granted Allergan Inc. (NYSE:AGN) rights in the U.S. to co-promote migraine candidate Levadex to neurologists and pain specialists. Map plans to submit an NDA this half for the product. Map will...
Items per page:
1 - 10 of 14